Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

SCLC diagnosis involves imaging, biopsies, and lab tests to assess tumor spread and guide treatment decisions. Treatment options vary by stage, with surgery, chemotherapy, radiation, and immunotherapy ...

DURHAM, N.C. (WTVD) -- Small cell lung cancer is one of the most aggressive and deadly forms of lung cancer commonly associated with smoking. Now, researchers at Duke Health have uncovered a ...

CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The publication of a multi-institutional study ...

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer Patients were randomly assigned to ...

Please provide your email address to receive an email when new articles are posted on . Patients with small cell lung cancer who had higher levels of detectable ctDNA mutations at diagnosis had worse ...